Among firms presenting on the first day, 10x Genomics revealed it is developing a new high-throughput Chromium instrument, and Guardant plans to launch a comprehensive tissue sequencing assay.
Q2 Solutions will run Adaptive's NGS-based immune cell receptor profiling assay for its pharma and biotech clients, potentially in COVID-19 vaccine trials.
Development revenues for the Seattle-based firm ticked up 5 percent to $15.0 million in Q3, partially offset by a 3 percent dip in sequencing revenues.
An international team of researchers put nine immune cell sequencing methods head to head, including RNA-based and DNA-based ones, using the same T-cell sample.
The immune sequencing firm also provided an update on the development of its ImmunoSeq Dx clinical product for detecting prior infection with SARS-CoV-2.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
